Short- and Long-Term Soy Diet Versus Casein Protects Liver Steatosis Independent of the Arginine Content

다국어 초록 (Multilingual Abstract)

Nonalcoholic fatty liver disease, a major cause of abnormal liver function, is often associated with obesity. Arginine (ARG) plays a role in modulating body weight/fat, but limited data exist as to the role of ARG in soy protein’s ability to protect from liver steatosis. We investigated the role of native ARG in the soy protein isolate (SPI) in reducing liver steatosis in male obese Zucker rats. Rats (N = 48; 6 weeks old) were randomly assigned to one of three diets for 8 or 16 weeks: the casein (CAS) diet as control (0.6% ARG), CAS diet supplemented to contain 1.3% ARG, or an SPI diet containing isoflavones (1.3% ARG). SPI and ARG rats gained significantly more weight (P < .05) than CAS rats after 16 weeks only. The SPI rats had lower liver steatosis scores after 8 and 16 weeks (P < .05 and P < .001, respectively) compared to CAS and ARG rats. SPI rats had lower serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (P < .05) compared to CAS after 16 weeks, and AST was lower (P < .05) compared to ARG rats. After 16 weeks, the SPI rats had lower (P < .05) serum ALT and AST levels than at 8 weeks. Our results suggest that a longer period of SPI feeding results in lower liver steatosis and serum ALT and AST levels, while the ARG diet had no effect on steatosis or ALT and AST levels. We found that the SPI diet reduced (P < .001) serum tumor necrosis factor-α (TNF-α) compared to CAS and ARG diets after 8 and 16 weeks. The SPI diet significantly reduced (P < .001) interleukin-6 (IL-6) when compared to the CAS diet at 8 weeks, but there was no significant difference at 16 weeks. Based on the findings of our study, the protective effect of SPI in reducing liver steatosis is not modulated by its native arginine content.

참고문헌 (Reference)

1 Gilbert W, "Trans–trans conjugated linoleic acid enriched soybean oil reduces fatty liver and lowers serum cholesterol in obese Zucker rats" 46 : 961-968, 2011

2 Lee J, "Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox" 100 : 4843-4848, 2003

3 Ra¨thel TR, "The soy isoflavone genistein induces a late but sustained activation of the endothelial nitric oxide-synthase system in vitro" 144 : 394-399, 2005

4 Sheu F, "Suppression effect of soy isoflavones on nitric oxide production in RAW 264.7 macrophages" 49 : 1767-1772, 2001

5 Jenkins DJA, "Soy protein reduces serum cholesterol by both intrinsic and food displacement mechanisms" 140 : 2302-2311, 2010

6 Tovar A, "Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats" 46 : 1823-1832, 2005

7 Cain J, "Soy protein isolate modified metabolic phenotype and hepatic wnt signaling in obese Zucker rats" 43 : 774-781, 2011

8 Ascencio C, "Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats" 134 : 522-529, 2004

9 Mezei O, "Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells" 133 : 1238-1243, 2003

10 Aguirre L, "Several statins increase body and liver fat accumulation in a model ofmetabolic syndrome" 64 : 281-288, 2013

11 Tan Be, "Regulatory roles for L-arginine in reducing white adipose tissue" 17 : 2237-2246, 2012

12 Jobgen WS, "Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates" 17 : 571-588, 2006

13 Mokdad AH, "Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001" 289 : 76-79, 2003

14 Browning JD, "Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity" 40 : 1387-1395, 2004

15 Flegal KM, "Prevalence and trends in obesity among US adults, 1999–2008" 303 : 235-241, 2010

16 Wu G, "Pharmacokinetics and safety of arginine supplementation in animals" 137 : 1673S-1680S, 2007

17 Mingorance C, "Oral supplementation of propionyl-lcarnitine reduces body weight and hyperinsulinaemia in obese Zucker rats" 102 : 1145-1153, 2009

18 Hakkak R, "Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female Zucker rats" 7 : R627-R633, 2005

19 Hakkak R, "Obesity increases the incidence of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in an ovariectomized Zucker rat model" 30 : 557-563, 2007

20 Qiu LX, "Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease" 21 : 1099-1107, 2015

21 National Health and Nutrition Examination Survey, "National Center for Health Statistics"

22 National Health and Nutrition Examination Survey, "National Center for Health Statistics"

23 Anderson JW, "Meta-analysis of the effects of soy protein intake on serum lipids" 333 : 276-282, 1995

24 Zhan S, "Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile" 81 : 397-408, 2005

25 Fukunishi S, "Long-term feeding of a synthetic diet rich in disaccharides induces hepatic fibrosis in nonalcoholic fatty liver disease in Zucker rats" 25 : 187-193, 2010

26 Kim MH, "Isoflavones as a smart curer for non-alcoholic fatty liver disease and pathological adiposity via ChREBP and Wnt signaling" 54 : S57-S63, 2012

27 Zucker LM, "Insulin and obesity in the Zucker genetically obese rat ‘‘fatty’’" 90 : 1320-1330, 1972

28 Hijona E, "Inflammatory mediators of hepatic steatosis" 2010 : 7-, 2010

29 Ong JP, "Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease" 49 : 608-612, 2008

30 Wergedahl H, "Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats" 134 : 1320-1327, 2004

31 Zhou D, "Fat accumulation in the liver of obese rats is alleviated by soy protein isolate through b-catenin signaling" 22 : 151-158, 2014

32 Bray G, "Experimental obesity: A homeostatic failure due to defective nutrient stimulation of the sympathetic nervous system" 45 : 1-125, 1989

33 Ong JP, "Epidemiology and natural history of NAFLD and NASH" 11 : 1-16, 2007

34 Gudbrandsen OA, "Dietary soya protein concentrate enriched with isoflavones reduced fatty liver, increased hepatic fatty acid oxidation and decreased the hepatic mRNA level of VLDL receptor in obese Zucker rats" 96 : 249-257, 2006

35 Hakkak R, "Dietary soy protein induces hepatic lipogenic enzyme gene expression while suppressing hepatosteatosis in obese female Zucker rats bearing DMBA-initiated mammary tumors" 7 : 549-558, 2012

36 Gudbrandsen OA, "Dietary single cell protein reduces fatty liver in obese Zucker rats" 100 : 776-785, 2008

37 Gudbrandsen OA, "Dietary proteins with high isoflavone content or low methionineglycine and lysine-arginine ratios are hypocholesterolaemic and lower the plasma homocysteine level in male Zucker fa/fa rats" 94 : 321-330, 2005

38 Fu WJ, "Dietary l-arginine supplementation reduces fat mass in Zucker diabetic fatty rats" 135 : 714-721, 2005

39 Korourian S, "Diet and risk of ethanol-induced hepatotoxicity: Carbohydrate-fat relationships in rats" 47 : 110-117, 1999

40 Wu G, "Arginine metabolism: Nitric oxide and beyond" 336 (336): 1-17, 1998

41 Lim DW, "Anti-obesity effect of artemisia capillaris extracts in high-fat diet-induced obese rats" 18 : 9241-9252, 2013

42 Kern PA, "Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression" 52 : 1779-1785, 2003

43 Buque´ X, "A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats" 51 : 500-513, 2010

44 Tovar AR, "A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome" 132 : 2562-2569, 2002

45 Gudbrandsen O, "A casein diet added isoflavone-enriched soy protein favorably affects biomarkers of steatohepatitis in obese Zucker rats" 25 : 574-580, 2009